Related references
Note: Only part of the references are listed.Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase
Rodrigo F. Ortiz-Meoz et al.
CHEMBIOCHEM (2021)
Degradation of proteins by PROTACs and other strategies
Yang Wang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer Related Targets
Ziga Skok et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors
Xiaohan Song et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors
Guonan Cui et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors
Yi-Hui Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3
Rizhen Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors
Wieslaw M. Kazmierski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation
Giada Mondanelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors
Brendan T. Parr et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
Mingxing Hu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity
Marta Serafini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)
Catherine White et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)
Shulei Pan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
Lijie Zhai et al.
FRONTIERS IN IMMUNOLOGY (2020)
Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
Lauren M. F. Merlo et al.
FRONTIERS IN IMMUNOLOGY (2020)
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Dhanusha A. Nalawansha et al.
CELL CHEMICAL BIOLOGY (2020)
4,6-Substituted-1 H-Indazoles as potent IDO1/TDO dual inhibitors
Lingling Yang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Alexander J. Muller et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Discovery of Clinical Candidate (1R,4r)-44(R)-24(S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1
Sanjeev Kumar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors
Wangyang Tu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Ute F. Rohrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Echoes of a failure: what lessons can we learn?
Vernon K. Sondak et al.
LANCET ONCOLOGY (2019)
Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors
Shulun Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer
Qianming Du et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase
Dan Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeted protein degradation: expanding the toolbox
Matthieu Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy
Hongjun Zhang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase
Maria Winters et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Delivery technologies for cancer immunotherapy
Rachel S. Riley et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Immune control by amino acid catabolism during tumorigenesis and therapy
Henrique Lemos et al.
NATURE REVIEWS CANCER (2019)
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Xiu-Xiu Wang et al.
MEDCHEMCOMM (2019)
IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation (vol 26, pg 357, 2014)
Richard Metz et al.
INTERNATIONAL IMMUNOLOGY (2019)
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair et al.
FRONTIERS IN IMMUNOLOGY (2019)
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Ian Churcher
JOURNAL OF MEDICINAL CHEMISTRY (2018)
A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies
Alessia Griglio et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
A patent review of IDO1 inhibitors for cancer
Jae Eun Cheong et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
Dnyandev B. Jarhad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form
Micah T. Nelp et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
A new cancer immunotherapy suffers a setback
Ken Garber
SCIENCE (2018)
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors
Kun Fang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Combination Immunotherapy in Non-small Cell Lung Cancer
Melina E. Marmarelis et al.
CURRENT ONCOLOGY REPORTS (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
Theodoros Eleftheriadis
FRONTIERS IN IMMUNOLOGY (2018)
Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1
E. Albini et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Proteolysis Targeting Chimera (PROTAC): A Paradigm-Shifting Approach in Small Molecule Drug Discovery
Pingyuan Wang et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives
Shengnan Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1
Khoa N. Pham et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Takefumi Komiya et al.
FRONTIERS IN ONCOLOGY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indo1-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate
Stefano Crosignani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Discovery of IDO1 and DNA dual targeting antitumor agents
Kun Fang et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1
Ariel Lewis-Ballester et al.
NATURE COMMUNICATIONS (2017)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Discovery of IDO1 Inhibitors: From Bench to Bedside
George C. Prendergast et al.
CANCER RESEARCH (2017)
In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2017)
Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy
Philipp Ottis et al.
ACS CHEMICAL BIOLOGY (2017)
Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties
Shan Qian et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Henrique Lemos et al.
CANCER RESEARCH (2016)
Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors
Juanjuan Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Differential effects of the two amino acid sensing systems, the GCN2 kinase and the mTOR complex 1, on primary human alloreactive CD4+ T-cells
Theodoros Eleftheriadis et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective
Luca Carlino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells
Olga Novikov et al.
MOLECULAR PHARMACOLOGY (2016)
Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans
Jason Boer et al.
DRUG METABOLISM AND DISPOSITION (2016)
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
Ute F. Roehrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Tryptophan-degrading enzymes in tumoral immune resistance
Nicolas van Baren et al.
FRONTIERS IN IMMUNOLOGY (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production
Margaret M. Lowe et al.
PLOS ONE (2014)
Crystal Structures and Structure Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors
Shingo Tojo et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Hatem H. Soliman et al.
ONCOTARGET (2014)
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
In Silico Identification of an Aryl Hydrocarbon Receptor Antagonist with Biological Activity In Vitro and In Vivo
Ashley J. Parks et al.
MOLECULAR PHARMACOLOGY (2014)
Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice
Shuangshuang Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2013)
An expanding range of targets for kynurenine metabolites of tryptophan
Trevor W. Stone et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Regulation of Immune Responses by mTOR
Jonathan D. Powell et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Modulation of Cytochrome-P450 Inhibition (CYP) in Drug Discovery: A Medicinal Chemistry Perspective
Sanjay Kumar et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan
Richard Metz et al.
ONCOIMMUNOLOGY (2012)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Maria T. Pallotta et al.
NATURE IMMUNOLOGY (2011)
Cancer immunotherapy - revisited
W. Joost Lesterhuis et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
External influences on the immune system via activation of the aryl hydrocarbon receptor
Brigitta Stockinger et al.
SEMINARS IN IMMUNOLOGY (2011)
Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
Anthony E. Boitano et al.
SCIENCE (2010)
Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling
Brett C. DiNatale et al.
TOXICOLOGICAL SCIENCES (2010)
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model
Eddy W. Yue et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Inhibitory Substrate Binding Site of Human Indoleamine 2,3-Dioxygenase
Changyuan Lu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase
Sanjeev Kumar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis
Ciriana Orabona et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Crystal structure of human indoleamine 2,3-dioxygenase:: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase
H Sugimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
DH Munn et al.
IMMUNITY (2005)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Share Paper
